Ocugen (OCGN) traded higher in the premarket on Thursday after the company said that OCU410, its gene therapy for an eye disorder called geographic atrophy (GA) secondary to dry age-related macular degeneration, caused a 46% lesion reduction in a mid-stage trial at 12 months.
